by 
Urinary tract infections (UTIs) are among the most common bacterial infections, affecting millions of people worldwide each year. UTIs occur when bacteria enter the urinary tract via the urethra.
UTIs are categorized as uncomplicated or complicated depending on the type of infectious agent and location of infection in the urinary tract. UTIs can affect any part of the urinary system including the kidneys, ureters, bladder, and urethra. Common symptoms of UTIs include pain or burning sensation during urination, frequent and urgent need to urinate, urinating small amounts of urine, and cloudy or bloody urine.
The most prevalent bacterial causes of UTIs are Escherichia coli (E. coli), Staphylococcus saprophyticus, Klebsiella, Proteus, Pseudomonas, and Enterobacter species. Therapeutics for UTIs aim to eliminate the bacterial infection and provide relief from symptoms. Antibiotics such as fluoroquinolones, trimethoprim/sulfamethoxazole, and ß-lactams are commonly prescribed to treat UTIs.
The global Urinary Tract Infection Therapeutics Market is estimated to be valued at US$ 8,665.5 Mn in 2023 and is expected to exhibit a CAGR of 3.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Rising awareness regarding prevention of recurrent UTIs has increased the demand for therapeutic products targeting vaginal health. To address this, key players are developing enhanced therapeutic formulations. For instance, in June 2022, Evofem Biosciences launched EVO100 vaginal gel for the prevention of urinary tract infections. EVO100 was approved by USFDA in 2020. It works by maintaining vaginal pH and acidity levels, preventing infection-causing bacteria from multiplying. Such advancements in therapeutic formulations are expected to drive the growth of the urinary tract infection therapeutics market during the forecast period.
Porter’s Analysis
Threat of new entrants: The entry barriers in the urinary tract infection therapeutics market are moderate due to stringent regulations.
Bargaining power of buyers: The bargaining power of buyers is moderate due to the availability of generic products.
Bargaining power of suppliers: The bargaining power of suppliers is low as there are numerous ingredient suppliers.
Threat of new substitutes: The threat of new substitutes is low due to lack of viable treatment alternatives.
Competitive rivalry: The competitive rivalry is high among existing players due to increasing generic competition.
Key Takeaways
The global urinary tract infection therapeutics market is expected to witness high growth over the forecast period. The global Urinary Tract Infection Therapeutics Market is estimated to be valued at US$ 8,665.5 Mn in 2023 and is expected to exhibit a CAGR of 3.0% over the forecast period 2023 to 2030.
North America is expected to hold the largest share in the urinary tract infection therapeutics market during the forecast period. This is attributed to the rising prevalence of urinary tract infections and established healthcare infrastructure in the region. According to the Centers for Disease Control and Prevention (CDC), nearly 50% of women are diagnosed with a UTI during their lifetime.
Key players: Key players operating in the urinary tract infection therapeutic market are Pfizer, Novartis AG, Cipla Inc., Bayer AG, AstraZeneca, Shionogi & Co. Ltd., and GlaxoSmithKline PLC, among others. Pfizer’s treatment landscape includes nitrofurantoin, sulfamethoxazole/trimethoprim, and fosfomycin tromethamine.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
